[Congressional Record Volume 141, Number 92 (Wednesday, June 7, 1995)]
[House]
[Page H5686]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
LIFE EXTENDING AND LIFE SAVING DRUG ACT
The SPEAKER pro tempore. Under a previous order of the House, the
gentleman from Pennsylvania [Mr. Fox] is recognized for 5 minutes.
Mr. FOX of Pennsylvania. Madam Speaker, as was aptly described by
Carl B. Feldbaum, president of the BioTech Industry Organization,
``Life-saving new drugs do take too long to reach the people who need
them.''
From my district in Montgomery County, PA, I have heard many a
compelling story from constituents with cancer, Lou Gehrig's Disease,
epilepsy, or AIDS who speak of the difficulties in accessing the
medicines they need because the approval process in our country is so
prolonged and, in effect, they have to turn to other countries where
the products are available.
Don't get me wrong. The Food and Drug Administration serves a
valuable purpose in maintaining
high safety and efficacy standards. However, it is important to note
that the FDA's actions directly affect the lives of patients and the
ability of physicians to provide state-of-the-art care for their
patients.
In addition, the FDA regulates businesses that produce 25 percent of
America's gross national product, so the Agency's actions also impact
our country's economic well-being. The pharmaceutical industry is an
excellent example. The United States leads the world in discovering new
drugs yet, all too often, these drugs are available overseas first. The
United States is far and away the world leader in biotechnology, but
many biotechnology firms are moving clinical trials overseas because of
red tape imposed on them by the FDA. These are very troubling trends
that do not bode well for the economic future of the United States, or
for the economic future of Pennsylvania.
In my 13th Congressional District of Pennsylvania alone, we have 10
facilities of 4 major pharmaceutical companies. Together, these
facilities employ more than 11,000 people. I would not want to see any
of these constituents lose their jobs because FDA regulation is
prompting companies to conduct some of their work overseas.
Americans want safe medicines. They want a strong FDA that will keep
unsafe products off the market but, I believe, they want to see more
emphasis on the value of giving patients quicker access to safe and
effective new medicines. That is why, today, I am introducing the Life
Extending and Life Saving Drug Act. We need to take action as soon as
possible for the great benefit of this Nation's patients, physicians,
and our emerging industry. I look forward to working with my colleagues
to act quickly on this critical piece of legislation.
____________________